Sumitovant Enters into an Agreement for “Going Private” TransactionGoing Private Transaction Agreement • November 13th, 2020
Contract Type FiledNovember 13th, 2020Sumitovant Biopharma Ltd. (“Sumitovant”), a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura, “Sumitomo Dainippon Pharma”), and Urovant Sciences Ltd.(“Urovant”), consolidated subsidiary of Sumitomo Dainippon Pharma, announced on November 12 (local time) that they have entered into a definitive agreement where Sumitovant would make Urovant its wholly-owned subsidiary (the “Transaction”) as follows.
Pacific International Group Holdings LLC Las Vegas, NV 89117 May 17, 2011Going-Private Transaction Agreement • May 18th, 2011 • Platinum Energy Resources Inc • Crude petroleum & natural gas • New York
Contract Type FiledMay 18th, 2011 Company Industry JurisdictionWe understand that you are the registered and beneficial holder of 104,799 shares of Common Stock, par value $0.0001 per share, of the Company (“Shares”), represented by stock certificate number C-0058.